GSK negotiates 9 billion dollar Nuvalent acquisition
GSK is in talks to buy cancer drugmaker Nuvalent for over 9 billion dollars. The parties aim to reach an agreement on the acquisition as early as this week.
Xurve View
Insights:
Xurve View
GSK PLC is in talks to acquire cancer drugmaker NUVALENT INC-A for more than $9 billion. The potential deal values Nuvalent between $9 billion and $10 billion, representing a significant premium over its $7 billion market value. A successful acquisition would allow the United Kingdom pharmaceutical giant to expand its oncology pipeline through targeted therapies.
